Volume 8 Supplement 1
Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis
Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
© Angelis and Kanavos 2015
Published: 5 October 2015
There is increased recognition that economic evaluation has limitations because it does not capture a number of important dimensions of value. This may lead to a lack of comprehensiveness and a lack of transparency.
Past research has indicated that Multiple Criteria Decision Analysis (MCDA) could be used as an alternative methodology for assessing the value of new medical technologies in the context of Health Technology Assessment (HTA). The objective of this study is to apply in practice an MCDA framework for the value assessment of a set of therapeutic options in metastatic colorectal cancer through a simulation exercise based on MCDA principles.
A process to inform the value assessment of new medical technologies which, in turn, can help determine coverage decisions and possibly pricing mechanisms.
All stages of the framework were informed by extensive stakeholder engagement through their participation at a decision conference workshop. Stakeholders (13 in total) included health care professionals (e.g. clinical experts), methodology experts (e.g. health economists) and patient advocates (e.g. patients and carers), while adopting the perspective of a decision-making HTA body.
The context of the study relates to England and Wales at a national level (EURO region), but it can be applicable across all WHO regions and levels.
Study design: experimental case study
Time period: January 2015-May 2015.
Setting: to inform coverage decisions for cancer medicines used in inpatient settings
Interventions: application of a pre-existing methodological framework and experimental case study through a decision conference.
Value parameters considered included therapeutic, safety, innovation and socioeconomic criteria. Three alternative treatments were ranked based on their overall value, using value scores reflecting their performance across all the criteria while considering their relative importance, as informed through stakeholders' preferences. Simulation of payer's resource allocation decisions on the coverage of the options were made on value for money grounds through the use of a “cost-per-unit of value” metric.
MCDA possesses the prerequisites of a value-based assessment methodological framework. The multiplicity of criteria that can be incorporated to assess value, the weights that can be applied to the criteria and the stakeholders' involvement across every stage, all of which are fully transparent, provide a unique combination of broadness, resilience and inclusiveness making it an ideal decision-making tool.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.